Menarini Receives European Commission Approval of ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

– ELZONRIS is the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, in Europe – Approval is based on the results of the largest prospective clinical trial ever conducted in patients with treatment-naïve or previously-treated BPDCN The Menarini Group, a privately held Italian pharmaceutical and diagnostics company, announced today that […]

thaipr.net

22 ม.ค. 64
1 3,224 3,225 3,226 3,227 3,228 3,348